Table 2. Uni-variate and multivariate Cox regression analyses results for evaluating variables associated with overall survival in lymph node positive group.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Unadjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |
| Pathologic T stage | ||||||
| Non-muscle invasive (pT0/Ta/T1/CIS) | Reference | Reference | ||||
| Muscle invasive (pT2) | 1.08 | 0.32–3.59 | 0.898 | 0.87 | 0.22–3.48 | 0.841 |
| Extravesical (pT3/T4) | 3.18 | 1.10–9.13 | 0.032 | 1.23 | 0.33–4.58 | 0.753 |
| Variant histology of UC | ||||||
| Absent | Reference | Reference | ||||
| Present | 3.53 | 1.88–6.64 | <0.001 | 3.54 | 1.77–7.08 | <0.001 |
| CIS | ||||||
| Absent | Reference | Reference | ||||
| Present | 0.42 | 0.18–0.94 | 0.035 | 0.48 | 0.20–1.12 | 0.093 |
| LVI | ||||||
| Absent | Reference | Reference | ||||
| Present | 2.05 | 1.09–3.88 | 0.026 | 2.78 | 1.41–5.47 | 0.003 |
| Pathologic nodal stage | ||||||
| N1 | Reference | |||||
| N2 | 1.70 | 0.94–3.08 | 0.080 | |||
| N3 | 1.78 | 0.59–5.34 | 0.305 | |||
| Number of removed LNs (continuous) | 0.96 | 0.93–0.99 | 0.022 | 0.98 | 0.95–1.01 | 0.335 |
| LND, dichotomized | ||||||
| <18% | Reference | Reference | ||||
| ≥18% | 2.27 | 1.28–4.02 | 0.005 | 2.09 | 1.16–3.77 | 0.013 |
HR = hazard ratio; CI = confidence interval; UC = urothelial carcinoma; CIS = carcinoma in situ; LVI = lymphovascular invasion; LND = lymph node density.